Japan’s Meiji Holdings says drug unit started late-stage trial for COVID vaccine
A health care worker prepares coronavirus tests in a lab at a COVID drive-thru testing center at Bergen Community College, as the global outbreak of the coronavirus disease (COVID-19) continues, in Paramus, New Jersey, U.S., December 3, 2020. REUTERS
Meiji Holdings Co. of Japan reported on Tuesday that its biopharmaceutical company has begun a Phase III study of an mRNA-based COVID-19 vaccine.
Meiji Seika Pharma announced in a statement that the late-stage experiment involving 780 participants had begun and will go from November to April 2024.